Boehringer Ingelheim Vetmedica GmbH

Firma Premium

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview

 

TwitterLinkedinTelegramTelegram

Understanding Pig Health​

Multiple pathogens and systems interact every day, shaping performance.​ Explore how these interactions can impact outcomes across systems.​
Gefällt mirkommentieren
teilen
Meine Favoriten
TwitterLinkedinTelegramTelegram

Boehringer Ingelheim at IPVS 2026: Promoting Swine Health Through Science, Prevention and Collaboration

The session highlighted the Dynamic Pig Health approach, showing how PRRS, PCV2, and Lawsonia interact in the field and reinforcing the need for holistic disease control strategies
Gefällt mirkommentieren
teilen
Meine Favoriten
TwitterLinkedinTelegramTelegram

ESPHM 2026- Does a booster vaccination at the start of the fattening period improve control of Mycoplasma hyopneumoniae infection in pigs?

Pigs that were boost vaccinated showed improved productive performance, with higher ADWG, greater live weight, and carcass weight.
Gefällt mirkommentieren
teilen
Meine Favoriten
TwitterLinkedinTelegramTelegram

ESPHM 2026 - Comparative evaluation of two vaccination protocols for Mesomycoplasma hyopneumoniae under field conditions

Under the conditions of the present study, the investment of a M.hyo. boost dose translated to a return on investment(ROI) of 1:10 only considering the reduction of mortality
Gefällt mirkommentieren
teilen
Meine Favoriten
TwitterLinkedinTelegramTelegram

ESPHM 2026 - Case Report: Impact of Mass Sow Vaccination Against Mycoplasma hyopneumoniae on Piglet Colonization at Weaning

Mass vaccination of sows against M. hyo is a reliable strategy to limit pathogen transmission in modern swine production
1 Gefällt mirkommentieren
teilen
Meine Favoriten

Kontakt:

Kontaktieren Sie uns über das folgende Formular.

Boehringer Ingelheim Vetmedica GmbH ist in den folgenden Kategorien vertreten